SCHEMBL4273684

SCHEMBL4273684

CCCCC[CH]CCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.61
PPARD Q03181 5/20 0.61
PPARA Q07869 5/20 0.61
TERT O14746 3/20 0.61
PTPN1 P18031 3/20 0.61
MAPT P10636 3/20 0.61
BLM P54132 3/20 0.61
HSD17B10 Q99714 3/20 0.61
FABP4 P15090 3/20 0.61
TOP1 P11387 3/20 0.61
USP2 O75604 2/20 0.61
LMNA P02545 2/20 0.61
ALOX15 P16050 2/20 0.61
RECQL P46063 2/20 0.61
F7 P08709 2/20 0.61
CYP19A1 P11511 2/20 0.61
F3 P13726 2/20 0.61
PTGS1 P23219 2/20 0.61
NR4A2 P43354 2/20 0.61
KMT2A Q03164 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28172819 0.98 PPARG (0.64) PPARGPPARDPPARATERTPTPN1
SCHEMBL297328 0.98 PPARG (0.64) PPARGPPARDPPARATERTPTPN1
SCHEMBL28317229 0.98 PPARG (0.64) PPARGPPARDPPARATERTPTPN1
SCHEMBL5695667 0.96 PPARG (0.62) PPARGPPARDPPARATERTPTPN1
SCHEMBL4272397 0.93 F7 (0.57) PPARGPPARDPPARATERTPTPN1
SCHEMBL7786847 0.91 TOP1 (0.70) PPARGPPARDPPARATERTPTPN1
SCHEMBL7784335 0.91 PPARG (0.73) PPARGPPARDPPARATERTPTPN1
SCHEMBL27699499 0.89 PPARG (0.77) PPARGPPARDPPARATERTPTPN1
SCHEMBL28215391 0.89 PPARG (0.77) PPARGPPARDPPARATERTPTPN1
SCHEMBL27879390 0.89 TOP1 (0.74) PPARGPPARDPPARATERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605263-B2 Fluorescent naphthalene-1,4,5,8-tetracarboxylic bisimides with an electron-donating substituent on the nucleus INFINEON TECHNOLOGIES AG (DE) 2009-10-20 US disclosed
EP-1313735-B1 LIQUID CRYSTALLINE 3,4:9,10-PERYLENETETRACARBOXYLIC ACID DIIMIDES BASF SE (DE) 2008-04-23 EP disclosed
US-6806368-B2 FOR ELECTRONIC, OPTOELECTRONIC AND PHOTONIC APPLICATIONS, FOR COLORATION OF MACROMOLECULAR ORGANIC AND OF INORGANIC MATERIALS BASF AKTIENGESELLSCHAFT (DE) 2004-10-19 US disclosed
US-20030181721-A1 Liquid crystalline 3,4:9,10-perylenetetacarbocylic acid diimides BASF AKTIENGESELLSCHAFT (DE) 2003-09-25 US disclosed
US-20030153005-A1 Fluorescent naphthalene -1,4,5,8-tetracarboxylic bisimides with an electron-donating substituent on the nucleus POLARIS INNOVATIONS LIMITED (IE) 2003-08-14 US disclosed
EP-0873342-B1 1,7-DIAROXY- OR 1,7-DIARYLTHIO-SUBSTITUTED PERYLENE-3,4,9,10-TETRACARBOXYLIC ACIDS AND THEIR DIANHYDRIDES AND DIIMIDES BASF AG (DE) 2003-06-04 EP disclosed
EP-1313735-A1 LIQUID CRYSTALLINE 3,4:9,10-PERYLENETETRACARBOXYLIC ACID DIIMIDES BASF AKTIENGESELLSCHAFT (DE) 2003-05-28 EP disclosed
WO-2002014318-A1 LIQUID CRYSTALLINE 3,4:9,10-PERYLENETETRACARBOXYLIC ACID DIIMIDES BASF AKTIENGESELLSCHAFT (DE) 2002-02-21 WO disclosed
US-6326494-B1 LASER DYES BASF AKTIENGESELLSCHAFT (DE) 2001-12-04 US disclosed
US-6251903-B1 Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist COCENSYS, INC. 2001-06-26 US disclosed
US-5622952-A NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-04-22 US disclosed
US-5620978-A 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-04-15 US disclosed
US-5620979-A TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-04-15 US disclosed
EP-0743855-A1 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR ACEA PHARMACEUTICALS, INC. (US) 1996-11-27 EP disclosed
EP-0732942-A1 ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS ACEA PHARMACEUTICALS, INC. (US) 1996-09-25 EP disclosed
US-5514680-A ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) 1996-05-07 US disclosed
WO-1995018616-A2 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR ACEA PHARM INC (US) 1995-07-13 WO disclosed
WO-1995012417-A1 ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS ACEA PHARMACEUTICALS, INC. (US) 1995-05-11 WO disclosed
EP-0647137-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-04-12 EP disclosed
WO-1994000124-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF WEBER ECKARD (US) 1994-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153005-A1 Fluorescent naphthalene -1,4,5,8-tetracarboxylic bisimides with an electron-donating substituent on the nucleus H1-4, H1-3, H1-5 PPARG 3543/4885PPARD 3437/4885PPARA 4076/4885
US-20030181721-A1 Liquid crystalline 3,4:9,10-perylenetetacarbocylic acid diimides CCR9, CLTA, HAO2 PPARG 2022/4885PPARD 1701/4885PPARA 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.